KPF
PACB icon

K2 Principal Fund’s Pacific Biosciences PACB Stock Holding History

K2 Principal Fund’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-50,000
Closed -$257K – 296
2019
Q4 		$257K Buy
+50,000
New +$254K 0.02% 267

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
KLCMU
Kite Lake Capital Management (UK) London, United Kingdom $290M AUM 183.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

K2 Principal Fund's PACB Position: Q1 2020 in Review

K2 Principal Fund sold out of Pacific Biosciences (PACB) in Q1 2020, closing a stake of 15,300 shares — an estimated $79K sold.

K2 Principal Fund first reported a position in PACB in Q1 2019 and held it in 2 quarters. The position peaked at $1.17M in Q1 2019. 132 funds tracked by Wall St. Rank hold PACB as of Q1 2020.

  • K2 Principal Fund reported no remaining Pacific Biosciences position as of Q1 2020 after selling out during the quarter.
  • K2 Principal Fund sold 15,300 Pacific Biosciences shares in Q1 2020, an estimated $79K.
  • K2 Principal Fund first reported a position in Pacific Biosciences in Q1 2019 and held it in 2 quarters.
  • K2 Principal Fund's Pacific Biosciences position peaked at $1.17M in Q1 2019.
  • 132 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2020.

Based on K2 Principal Fund's 13F filing for Q1 2020, filed 15 May 2020.